Clinical impact on time to progression (TTP) of acneiform skin lesions in cetuximab-based regimens in colorectal cancer

15096 Background: Cetuximab, a chimeric IgG1 (immunoglobulin G1) monoclonal antibody that binds to the extracellular domain of EGFR, inhibits its activation and modulate tumor-cell growth. The pres...